A systematic review of more than 40 clinical studies confirms the efficacy of MSC cell therapy in treating osteoarthritis. Meta-analysis shows statistically significant pain reduction and joint function improvement compared to the placebo group.
The analyzed studies included a total of more than 2,500 patients with osteoarthritis of the knee, hip, and shoulder joints. Results show that MSC therapy reduces pain (measured by VAS scale) by an average of 45-73% and improves joint function (measured by WOMAC score) by 40-65%.
An important finding of the review is that MSC therapy effects are long-lasting. Most studies with 12-24 month follow-up report maintained therapeutic effects throughout the observation period, with some studies showing even gradual improvement over time.
The review also identified key factors affecting therapy success: patient age, osteoarthritis grade (better results in early stages), number of cells applied, and method of application.
GaiaCell incorporates the latest clinical evidence in its therapeutic protocols. Our GMP-certified manufacturing ensures consistent MSC cell quality, which is a prerequisite for reproducible and reliable therapeutic results.